Steve Pakola, Chief Medical Officer at REGENXBIO Inc. ($RGNX), made one open market sale of company shares in the last year, totaling $53,033. His most recent sale occurred on March 10, 2026. These sales rank 10,326th among 11,678 insiders in our database, well below the average of $8.6 million per insider across about 6.4 transactions. Pakola recorded no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 10, 2026 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | S | Common Stock | 5124 | $10.35 | 247,926.0000 | 51,689,000 | 2.02% | 0.01% |
| Feb. 1, 2026 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | F | Common Stock | 5267 | $11.16 | 253,050.0000 | 51,689,000 | 2.04% | 0.01% |
| Jan. 6, 2026 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Stock Options (Right to buy) | 35402 | $0.00 | 35,402.0000 | 51,689,000 | 9999.99% | 0.07% |
| Jan. 6, 2026 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Common Stock | 65847 | $0.00 | 258,317.0000 | 51,689,000 | 34.21% | 0.13% |
| Jan. 2, 2026 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | F | Common Stock | 18247 | $14.40 | 192,470.0000 | 51,689,000 | 8.66% | 0.04% |
| Feb. 1, 2025 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | F | Common Stock | 5263 | $8.07 | 210,717.0000 | 49,509,000 | 2.44% | 0.01% |
| Jan. 2, 2025 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Stock Options (Right to buy) | 103698 | $0.00 | 103,698.0000 | 49,509,000 | 9999.99% | 0.21% |
| Jan. 2, 2025 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | F | Common Stock | 13891 | $7.73 | 151,687.0000 | 49,509,000 | 8.39% | 0.03% |
| Jan. 2, 2025 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Common Stock | 64293 | $0.00 | 215,980.0000 | 49,509,000 | 42.39% | 0.13% |
| Aug. 1, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Common Stock | 58386 | $0.00 | 165,578.0000 | 43,734,000 | 54.47% | 0.13% |
| March 5, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | S | Common Stock | 12878 | $28.36 | 107,192.0000 | 43,734,000 | 10.73% | 0.03% |
| March 5, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | M | Stock Options (Right to Buy) | 12878 | $0.00 | 31,277.0000 | 43,734,000 | 29.17% | 0.03% |
| March 5, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | M | Common Stock | 12878 | $22.25 | 120,070.0000 | 43,734,000 | 12.01% | 0.03% |
| Jan. 2, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Stock Options (Right to buy) | 50875 | $0.00 | 50,875.0000 | 43,734,000 | 9999.99% | 0.12% |
| Jan. 3, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | S | Common Stock | 17237 | $17.39 | 107,192.0000 | 43,734,000 | 13.85% | 0.04% |
| Jan. 2, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | A | Common Stock | 32051 | $0.00 | 124,429.0000 | 43,734,000 | 34.70% | 0.07% |
| Jan. 2, 2024 | REGENXBIO Inc. | $RGNX | PAKOLA STEVE | Chief Medical Officer | F | Common Stock | 10385 | $17.95 | 92,378.0000 | 43,734,000 | 10.11% | 0.02% |